Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CAMP4 THERAPEUTICS CORPORATION (CAMP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CAMP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $19.91
1 Year Target Price $19.91
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 102.82M USD | Price to earnings Ratio - | 1Y Target Price 19.91 |
Price to earnings Ratio - | 1Y Target Price 19.91 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 1.30 - 12.30 | Updated Date 05/31/2025 |
52 Weeks Range 1.30 - 12.30 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.64 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 109743472 | Price to Sales(TTM) - |
Enterprise Value 109743472 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 315.31 | Enterprise Value to EBITDA - | Shares Outstanding 20161100 | Shares Floating 3915684 |
Shares Outstanding 20161100 | Shares Floating 3915684 | ||
Percent Insiders 35.4 | Percent Institutions 56.95 |
Analyst Ratings
Rating 3 | Target Price 19.91 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CAMP4 THERAPEUTICS CORPORATION
Company Overview
History and Background
CAMP4 Therapeutics Corp. was founded in 2016 and is a biotechnology company focused on discovering and developing RNA-based therapeutics. It aims to target diseases caused by genetic haploinsufficiency by increasing gene expression.
Core Business Areas
- RNA Activating Therapeutics: CAMP4 focuses on developing small molecule therapeutics that selectively upregulate gene expression by targeting regulatory RNAs.
Leadership and Structure
Details of the full leadership team and organizational structure can be found on CAMP4 Therapeutics' website and investor relations pages.
Top Products and Market Share
Key Offerings
- Antisense Oligonucleotide (ASO) Therapeutics: CAMP4 is developing ASO-based therapies designed to increase gene expression. Market share and specific revenue figures for individual products are not publicly available as they are in the development phase. Potential competitors include Ionis Pharmaceuticals and Biogen, who also develop ASO therapies.
Market Dynamics
Industry Overview
The RNA therapeutics industry is experiencing rapid growth due to advancements in understanding RNA biology and drug delivery technologies. Key drivers include the increasing prevalence of genetic diseases and the growing demand for personalized medicine.
Positioning
CAMP4 Therapeutics is positioned as a leader in developing therapeutics that selectively upregulate gene expression. Its competitive advantage lies in its proprietary technology platform targeting regulatory RNAs.
Total Addressable Market (TAM)
The TAM for RNA therapeutics is estimated to be billions of dollars, with projections varying based on disease targets and market penetration. CAMP4 is positioning itself to capture a significant share of this market by focusing on specific genetic diseases.
Upturn SWOT Analysis
Strengths
- Proprietary technology platform for targeting regulatory RNAs
- Strong scientific team with expertise in RNA biology
- Potential to address unmet medical needs in genetic diseases
- Partnerships and collaborations with other companies
Weaknesses
- Early-stage company with limited commercialized products
- High risk of failure associated with drug development
- Reliance on external funding
- Competition from established pharmaceutical companies
Opportunities
- Expansion of the technology platform to new disease targets
- Strategic partnerships with larger pharmaceutical companies
- Advancement of clinical trials
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other RNA-based therapies
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- IONS
- MRNA
- ALNY
Competitive Landscape
CAMP4's advantage lies in its unique technology. Disadvantages are competing with bigger and established players.
Growth Trajectory and Initiatives
Historical Growth: CAMP4's historical growth is characterized by the expansion of its research and development programs, partnerships, and funding rounds.
Future Projections: Future growth is dependent on the success of its clinical trials and the potential for commercialization of its therapeutic candidates.
Recent Initiatives: Recent initiatives include advancing its lead programs into clinical trials, securing additional funding, and expanding its intellectual property portfolio.
Summary
CAMP4 Therapeutics is a promising early-stage biotechnology company with a novel approach to RNA-based therapeutics. Its strength lies in its proprietary technology and experienced team. However, it faces significant risks associated with drug development and competition from larger companies. Future success depends on positive clinical trial results and securing additional funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CAMP4 THERAPEUTICS CORPORATION
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2024-10-11 | CEO, President & Director Mr. Joshua Mandel-Brehm | ||
Sector Healthcare | Industry Biotechnology | Full time employees 55 | Website https://www.camp4tx.com |
Full time employees 55 | Website https://www.camp4tx.com | ||
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.